Alnylam Fell 47% — a Growth Reset, Not a Broken Business

Alnylam Pharmaceuticals fell about 47% in a year, roughly 28% in a single day in late July, and now trades near $247, down some 38% for 2026 alone. During that slide the company did something it had never done in its two-plus decades of existence: it started printing real profit and real free cash flow. That mismatch — a compounding decline attached to a business crossing into cash generation — is worth looking at, because the reason investors dumped the stock matters more than the drop itself.

The selloff traces to one drug. Amvuttra, an RNA-interference therapy Alnylam developed for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a rare disease in which misfolded protein deposits damage the heart, won FDA approval in May 2025. The launch was explosive. By the second quarter of 2026 Amvuttra pulled in $1.01 billion in a single quarter — the first time the drug crossed the billion-dollar mark and total TTR sales grew 89% year over year.

The problem is that some of that breakneck growth was borrowed from the future. When a superior new option arrives for a disease patients have been treating with older stabilizer pills, there is a one-time surge of people who had been waiting for it. Alnylam's own language calls this "pent-up demand." In late July the company cut its full-year 2026 TTR revenue guidance from $4.4–4.7 billion to $4.2–4.5 billion, explaining that growth in second-line patients had moderated to a "normalized level" after that initial wave. Investors, conditioned to a launch that seemed to accelerate every quarter, had priced in more. The reset was painful.

This is the moment to separate tape pain from business pain. The guidance cut is real, and it is an operating change, not a mood swing — the growth rate genuinely slowed. But notice what the reset did not touch. The mid-point of the new range still implies about $4.35 billion of TTR sales for 2026, on top of a year that delivered Alnylam its first-ever annual profit. The company earned a GAAP net profit of $314 million in 2025, against a $278 million loss in 2024, and reported another $164.5 million of GAAP net income in Q2 2026 alone. Roughly $820 million of free cash flow has flowed over the trailing twelve months, helped by a business that throws off about 80% gross margins. It holds around $3.3 billion in cash and marketable securities.

A stock dropping 47% in the same window a company turns cash-flow positive inverts the usual arrangement. The market is still pricing the old risk profile — a money-losing growth story — while the operating setup has already gotten cleaner. That is precisely the expectations-reset contrast this approach hunts for. The headline says the ATTR-CM franchise is fading. The cash-flow path says the opposite: the business just crossed the inflection that turns scale into profit.

Now the candor, because this is not a free lunch. Priced at roughly 40 times trailing free cash flow, Alnylam is not cheap — that multiple still embeds an enormous, durable ATTR franchise, and a depressed multiple is only an opportunity when the operations underneath justify it, never on its own. Law firms, sensing a target after a crash, have begun advertising securities-fraud investigations into the guidance cut; that is routine noise after any sharp drop, but it is overhang, not thesis.

The harder question is competitive, and it is the one that will decide whether the reset becomes an entry or a warning. Amvuttra is a subcutaneous injection given every three months. Its rivals in ATTR-CM — Pfizer's tafamidis and BridgeBio's oral Attruby, which had a strong launch of its own — are daily pills. Alnylam's edge is meaningful compliance advantage, but its launch is no longer running unopposed, and the second-line surge it benefited from was partly a structurally more stable pool once normalized.

So the proof path and the break condition are the same number. The thesis survives if Amvuttra, on its normalized base, returns to consistent sequential growth through the next couple of quarters while free cash flow keeps scaling into 2027 — the point at which the profitability transition is no longer a novelty but a bankable stream. It breaks if normalized growth stalls: if new-patient uptake flags as pill competitors take share, or if diagnosis rates fail to compound the way the market assumes, then a 40-times-cash-flow multiple has no support and the decline was the market being right early, not just early.

I can be wrong again — the growth reset is real, and I have no idea which quarter the ATTR volume reaccelerates. But this is not about excitement. It is about a business that turned cash-flow positive for the first time in its history in the same year the crowd stopped caring, and about asking whether normalized growth can now carry that cash flow forward. Watch the quarterly Amvuttra sequentials and the cash pile. If the franchise reaccelerates into 2027, the 47% decline starts to look like the setup, not the story. If growth keeps fading, the reset was the correct conclusion all along.